Why Obesity Is Approached as a Chronic Condition
Weight regulation is not simply a matter of willpower; it is governed by appetite hormones, energy expenditure, sleep, medications, hormonal status and environmental factors. Once weight is lost, the body tends to develop a physiological response that favours regaining it. This is why treatments that 'end when the diet ends' are usually not enough in the long term for most people.
Treating obesity as a chronic condition means the treatment itself needs to be continuous. Just as a rise in blood pressure after stopping antihypertensive medication is not considered a personal failure, weight regain after stopping obesity treatment is not a personal failure either.
Comparing the Two Treatment Options
GLP-1/GIP-based medications work by mimicking gut-derived hormones that increase satiety, slow gastric emptying and alter central appetite signalling; in people with type 2 diabetes they can also help blood sugar control. Their effect depends on continued use, and common side effects include nausea, vomiting, constipation or diarrhoea, particularly during dose increases; less common but important issues include gallbladder problems and pancreatitis. Medication choice, dose escalation and monitoring should always be supervised by a physician.
Metabolic-bariatric procedures such as sleeve gastrectomy, gastric bypass and mini gastric bypass do more than reduce stomach volume; they also affect the release of appetite and satiety hormones, bile acid cycling and insulin sensitivity, which is why the term 'metabolic surgery' is used. Beyond weight loss, surgery may contribute to improvement in conditions such as type 2 diabetes, sleep apnoea, hypertension, fatty liver disease and joint strain, although this contribution varies between individuals and no method guarantees a specific outcome.
Medication is not a one-time decision — its benefit continues only as long as it is taken. Surgery is a single procedure but requires lifelong nutritional, vitamin and laboratory follow-up. Choosing between them is not only about which has a stronger effect, but about which the patient can sustain and is medically appropriate for.
How Eligibility Is Assessed in 2026
The joint 2022 ASMBS/IFSO statement updated the long-standing 1991 thresholds. Under this framework, metabolic-bariatric surgery may be recommended for people with a BMI of 35 kg/m² and above, regardless of whether a co-existing condition is present.
For a BMI in the 30–34.9 kg/m² range, surgical evaluation may be considered when a metabolic condition (particularly type 2 diabetes) is present, or when non-surgical methods have not achieved adequate and durable weight loss.
These thresholds are not an automatic indication for surgery. The decision follows a multidisciplinary evaluation that includes endoscopy, laboratory testing, anaesthesia assessment, and nutritional and psychological review.
Questions to Ask When Deciding
What has my weight history been? Which methods have I tried before, and for how long could I sustain them?
Do I have co-existing conditions? Would type 2 diabetes, sleep apnoea or uncontrolled hypertension change the picture?
Can I sustain medication over the long term? What about access, cost and my tolerance of side effects?
Can I commit to lifelong follow-up, vitamin supplementation and dietary changes after surgery?
Are my expectations realistic? Is my goal only a number on the scale, or metabolic health and function?
Weight Regain: A Consideration With Either Option
With medication, the effect continues only while it is used. Once medication is stopped, appetite and satiety signals tend to return towards baseline, and weight regain is common. If medication is to be stopped, this should be planned together with nutritional and activity support.
After surgery, some regain can also occur after the first one to two years. When regain is significant, eating habits, meal patterns, psychological factors and anatomical status are reviewed first; medication support or revisional surgery may be considered if appropriate.
Can Medication and Surgery Be Used Together?
Yes, in selected patients a combined approach may be considered. Before surgery, medical support may be considered to reduce liver volume and lower surgical risk.
After surgery, in patients with an insufficient response or significant weight regain, medication may be added following joint evaluation by the surgical team and endocrinology. This decision is individualised and is not routine practice.
Frequently Asked Questions
If I take medication, can I avoid surgery? In some people medication may be sufficient; in others, the targeted metabolic improvement is not achieved. This cannot be predicted in advance with certainty — the response is monitored and the decision is made accordingly.
Is surgery a 'last resort'? No. Within current guidance, surgery is considered a treatment option for suitable candidates that should not be unnecessarily delayed.
Which is safer? The risk profiles differ: with medication, the key considerations are the need for continuity and tolerance of side effects; with surgery, they are early surgical risks and long-term nutritional follow-up. Any comparison can only be made in the context of a person's own health status.
References
- ASMBS/IFSO — 2022 Indications for Metabolic and Bariatric Surgery (opens in a new tab)
- NICE NG246 — Overweight and obesity management (opens in a new tab)
- WHO (2025) — Global guideline on GLP-1 medicines for obesity (opens in a new tab)
- ASA (2024) — Multi-society GLP-1 perioperative guidance (opens in a new tab)
The results of any surgical or interventional procedure may vary from person to person. It is recommended that you obtain detailed advice from your physician before the procedure.
Last updated: · Patient information content
Site editor: atesdr@yahoo.com — Please do not send test results, reports, photographs or sensitive health data to this address.